Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma

Abstract

The distinction between epithelioid mesothelioma and lung adenocarcinoma remains an important diagnostic challenge for surgical pathologists. The aim of the present study was to select a limited and appropriate panel of antibodies that can differentiate between epithelioid mesothelioma and lung adenocarcinoma. Specimens of 90 epithelioid mesotheliomas and 51 lung adenocarcinomas obtained from Japanese cases were examined using calretinin, WT1, AE1/AE3, CAM5.2, cytokeratin (CK) 5/6, vimentin, epithelial membrane antigen (EMA), thrombomodulin, CEA, CA19-9, and CA125. Ninety-six percent of epithelioid mesotheliomas were positive for calretinin; 99% for WT1; 100% for AE1/AE; 97% for CAM5.2; 70% for CK 5/6; 91% for vimentin; 96% for EMA; 71% for thrombomodulin; 77% for mesothelin; 7% for CEA; 17% for CA19-9; and 85% for CA125. In contrast, 33% of lung adenocarcinomas were positive for calretinin; 16% for WT1; 100% for AE1/AE3, CAM5.2, and EMA; 41% for CK 5/6; 47% for vimentin; 20% for thrombomodulin; 69% for mesothelin; 98% for CEA; 73% for CA19-9; and 80% for CA125. For distinguishing between epithelioid mesothelioma and lung adenocarcinoma, the combination of CEA, calretinin and each WT1 or thrombomodulin was suggested to be the best panel of immunohistochemical markers.

Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms

“…10,38 In this study, combined use of the three antibodies that yielded 100% specificity for thymic carcinoma, that is, the antibodies for GLUT-1, CD5, and CEA, provided 91.6% sensitivity. Thus, combined use of these three antibodies should be useful for differentiating between thymic carcinoma and type B3 thymoma in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically.…”

Claudin 3 and 4 immunoreactivity in malign mesothelioma and lung adenocarcinoma

“…Bu zorluğu yenmede, immünhistokimyasal yöntemler patologlara yardımcı olmaktadır (17 (19). Ayrıca CD15 adenokarsinomlarda, mezotelyomalara göre daha yüksek oranda boyanma gösterir (17).…”

“…Bu zorluğu yenmede, immünhistokimyasal yöntemler patologlara yardımcı olmaktadır (17 (19). Ayrıca CD15 adenokarsinomlarda, mezotelyomalara göre daha yüksek oranda boyanma gösterir (17). Ordonez, mezotelyomaların adenokarsinomlardan ayrımında bir pozitif (kalretinin, sitokeratin 5/6 veya WT1) ve bir negatif (CEA, MOC31, B72.3 veya Ber-EP4) mezotelyoma belirleyicisinin kullanılmasını önermektedir (19).…”

Immunohistochemistry and Molecular Diagnostics of Pleural Malignant Mesothelioma

“…The summary of immunohistochemical staining results is presented in Table 1 Table 2, these results are compared to the latest published data. 13,[16][17][18] In addition to the above diagnostic markers, by now well known and widely used, a few novel antibodies, either ''positive'' or ''negative'' for MM, have recently been proposed, even though the freshly published results still require validation. Extracellular matrix glycoprotein tenascin-X is the largest member of the tenascin family and induces cell detachment by means of the intracellular p38 MAP (mitogen-activated protein) kinase pathway.…”